Daily Newsletter

12 September 2023

Daily Newsletter

12 September 2023

Nemaura completes study of sugarBEAT glucose monitor

The Class IIb medical device is approved in Europe and Saudi Arabia for a wear period of 14 hours.

September 12 2023

Nemaura Medical has completed a 100-patient study of the non-invasive and flexible continuous glucose monitor sugarBEAT.

Carried out in the Middle East, the study included four cohorts with an equal number of male and female subjects aged 18 to 75 years.

Out of the total patients, 20 had type 1 diabetes and the remaining had type 2 diabetes.

The Class IIb medical device is approved in Europe and Saudi Arabia for a wear period of 14 hours.

The study was designed to evaluate the possibility of increasing the wear period to up to 24 hours and assess different methods of device application to the skin, as well as the possibility of auto-calibration.

The interim data of the first cohort, including 25 patients on single-day sensor wear, over a 12-hour period demonstrated an overall mean absolute relative difference (MARD) of 9.8%, with 86% of the paired points within 20/20 of the reference value.

An overall MARD of 12.8% was observed over a 24-hour sensor wear period, based on 1,379 paired points, with 76% of the paired points within 20/20 of the reference blood serum glucose value.

These results indicate the possibility of using a single sensor for a 24-hour sensor wear period, allowing users to monitor their glucose fluctuations overnight.

The remaining cohorts are being evaluated to establish the extent to which auto-calibration may be feasible and to determine the optimal sensor application method.

The company’s other non-invasive wearable diagnostic devices include proBEAT.

Generative AI set to transform the medical devices industry

Generative AI can improve personalized healthcare by collecting data from patients via wearable devices, which can provide continuous, real-time data that can complement traditional data sources such as imaging, patient records, and more. It can also enhance existing imaging techniques by generating high-quality images of organs using data from low-resolution images (such as ultrasounds). However, the collection and use of patient healthcare data through AI medical products could conflict with regulations around the globe.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close